Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Anatara Lifesciences Ltd    ANR   AU000000ANR0

ANATARA LIFESCIENCES LTD (ANR)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Anatara Lifesciences Ltd (ASX:ANR) Annual Report 2017 Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 04:43am CET

Brisbane, Australia, Oct 4, 2017 - (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Annual Report 2017 Update.

The 2016-17 financial year saw the Company achieve several major milestones in readying our lead product Detach(R) for market launch.

The macro-environment continues to strengthen our cause, as the global issue of antibiotic resistance gains momentum on an international scale and consumer demand for antibiotic free meat continues to grow at a rapid pace. As a result, the need for a non-antibiotic product like Detach(R), which will assist pork producers to control scour (diarrhoea) in their piglets, is becoming even more critical.

The US's biggest food players continued to make progress toward ending routine antibiotic use, with many new initiatives within the last year. Kentucky Fried Chicken was the latest large restaurant chain to announce that it would discontinue purchasing chicken treated with antibiotics used in humans by 2018. Globally, the fast-food retailer McDonald's group is forging ahead with its plans to start curbing the use of important human antibiotics in its worldwide chicken supply. From January 2018, "highest priority critically important antimicrobials" (HPCIAs) will be removed from McDonald's chickens in Brazil, Canada, Japan, South Korea, the United States and Europe, with Australian and Russian suppliers following suit by the end of 2019.

Furthermore, in June 2017, after much debate, the European Commission's EMA Veterinary Committee handed down its final decision on the use of zinc oxide in feed. Zinc oxide is used widely across the European Union (EU) to prevent and control post-weaning diarrhoea (PWD) in young pigs. An estimated 70-90% of diets for young pigs in the UK contain zinc oxide at therapeutic levels (see Note below).

The Committee has now confirmed an EU-wide ban on the use of zinc oxide at medicinal levels in piglet feed, giving member states a maximum of five years to phase it out. This ban will necessitate the introduction of alternative products to aid in the control of diarrhoea in piglets.

Note: Driver, A, 21 June 2017, Member states given five years to ban zinc oxide, Pig World http://www.pig-world.co.uk

To view the full report, please visit:
http://abnnewswire.net/lnk/12827V9S


About Anatara Lifesciences Ltd:

Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.

Contact:

 
Investor inquiries:
Dr Mel Bridges
Chairman & CEO
Anatara Lifesciences
Phone: +61-413-051-600
Email: [email protected]

Media inquiries:
Jane Lowe
Managing Director
IR Department
Phone: +61-411-117-774
Email: [email protected] 

Copyright (C) 2017 ABN Newswire. All rights reserved., source Press Releases English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ANATARA LIFESCIENCES LTD
2017 Anatara Lifesciences Ltd Presents at Australasian Pig Science Association Co..
2017 ANATARA LIFESCIENCES LTD (ASX : ANR) Presents at Australasian Pig Science Associ..
2017 Anatara Lifesciences Ltd Chairman's Address to Shareholders
2017 ANATARA LIFESCIENCES LTD (ASX : ANR) Chairman's Address to Shareholders
2017 Anatara Lifesciences Ltd Dr Tracey Mynott Presents at TRI Science Business I..
2017 ANATARA LIFESCIENCES LTD (ASX : ANR) Dr Tracey Mynott Presents at TRI Science Bu..
2017 Anatara Lifesciences Ltd Investor Presentation
2017 Anatara Lifesciences Ltd Annual Report 2017 Update
2017 ANATARA LIFESCIENCES LTD (ASX : ANR) Annual Report 2017 Update
2017 Anatara Lifesciences Ltd Pork CRC Options Extended by 12 Months
More news
News from SeekingAlpha
2015 Coal stocks could be near a bottom, J.P. Morgan team says
2015 COMMODITIES TODAY : Solar Stocks Shoot Higher, Mining Property Market Hits Lows
2015 ALPHA NATURAL RESOURCES : Cutting Costs While Waiting For A Metallurgical Coal M..
2015 ALPHA NATURAL RESOURCES Q4 REVIEW : Margins, Liquidity And Growth In Focus
2015 Alpha Natural Resources' (ANR) CEO Kevin Crutchfield on Q4 2014 Results - Ear..
Financials ( AUD)
Sales 2018 3,69 M
EBIT 2018 -0,22 M
Net income 2018 -
Finance 2018 3,60 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 21,8x
EV / Sales 2019 10,1x
Capitalization 84,0 M
Chart ANATARA LIFESCIENCES LTD
Duration : Period :
Anatara Lifesciences Ltd Technical Analysis Chart | ANR | AU000000ANR0 | 4-Traders
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 1,78  AUD
Spread / Average Target 4,4%
Managers
NameTitle
Melvyn John Bridges Non-Executive Chairman & Chief Executive Officer
Michael Leo West Chief Operating Officer
Tracey Leahanne Mynott Chief Scientific Officer
Iain Gladstone Ross Independent Non-Executive Director
Tracie Elizabeth Ramsdale Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ANATARA LIFESCIENCES LTD-1.73%67
CELLTRION, INC.--.--%41 248
IQVIA HOLDINGS INC2.19%20 807
LONZA GROUP0.46%20 432
INCYTE CORPORATION-0.68%19 852
ALNYLAM PHARMACEUTICALS, INC.1.59%12 692